People with multiple myeloma are prone to experience significant workplace and functional impairment, high out of pocket costs, and frequent office visits, researchers concluded after conducting a cross-sectional study involving 162 individuals. Adherence to therapy can blunt the impact. Participants with multiple myeloma were divided into 2 groups according to their medication adherence scores. They completed 3 surveys, including the Functional Assessment of Cancer Therapy–Multiple Myeloma (FACT-MM): Among the results:
- FACT-MM scores averaged 98.5.
- Absenteeism and presenteeism averaged 18% and 52%, respectively.
- Work productivity and activity impairment averaged 57% and 50%, respectively.
- Out-of-pocket costs averaged ~$700 in the prior 3 months.
- Patients spent an average of ~7 hours in monthly appointments with clinicians.
- Patients with high medication adherence had higher FACT-MM scores.
- Those with lower medication adherence reported greater activity impairment and were more apt to be overwhelmed/frustrated with appointment rescheduling.
Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg A. Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2018.01.006.
This Week's Must Reads
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885
Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291
Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04
Outcomes better in TNBC with adjuvant chemotherapy within 30 days of surgery, Morante Z et al., SABCS 2018 Abstract GS2-05
Must Reads in Myelodysplastic Syndrome
Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.
JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.
Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4
Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al
Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al